These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18237401)

  • 1. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.
    Cao H; Alston L; Ruschman J; Hegele RA
    Lipids Health Dis; 2008 Jan; 7():3. PubMed ID: 18237401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Frame-Shift Mutation in CAV1 Is Associated with a Severe Neonatal Progeroid and Lipodystrophy Syndrome.
    Schrauwen I; Szelinger S; Siniard AL; Kurdoglu A; Corneveaux JJ; Malenica I; Richholt R; Van Camp G; De Both M; Swaminathan S; Turk M; Ramsey K; Craig DW; Narayanan V; Huentelman MJ
    PLoS One; 2015; 10(7):e0131797. PubMed ID: 26176221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome.
    Garg A; Kircher M; Del Campo M; Amato RS; Agarwal AK;
    Am J Med Genet A; 2015 Aug; 167A(8):1796-806. PubMed ID: 25898808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3' terminus of the FBN1-gene.
    Graul-Neumann LM; Kienitz T; Robinson PN; Baasanjav S; Karow B; Gillessen-Kaesbach G; Fahsold R; Schmidt H; Hoffmann K; Passarge E
    Am J Med Genet A; 2010 Nov; 152A(11):2749-55. PubMed ID: 20979188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical generalized lipoatrophy and severe insulin resistance due to a heterozygous LMNA p.T10I mutation.
    Mory PB; Crispim F; Kasamatsu T; Gabbay MA; Dib SA; Moisés RS
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1252-6. PubMed ID: 19169477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perilipin deficiency and autosomal dominant partial lipodystrophy.
    Gandotra S; Le Dour C; Bottomley W; Cervera P; Giral P; Reznik Y; Charpentier G; Auclair M; Delépine M; Barroso I; Semple RK; Lathrop M; Lascols O; Capeau J; O'Rahilly S; Magré J; Savage DB; Vigouroux C
    N Engl J Med; 2011 Feb; 364(8):740-8. PubMed ID: 21345103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy.
    Kozusko K; Tsang V; Bottomley W; Cho YH; Gandotra S; Mimmack ML; Lim K; Isaac I; Patel S; Saudek V; O'Rahilly S; Srinivasan S; Greenfield JR; Barroso I; Campbell LV; Savage DB
    Diabetes; 2015 Jan; 64(1):299-310. PubMed ID: 25114292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Premature atherosclerosis in a Japanese diabetic patient with atypical familial partial lipodystrophy and hypertriglyceridemia.
    Iwanishi M; Ebihara K; Kusakabe T; Harada S; Ito-Kobayashi J; Tsuji A; Hosoda K; Nakao K
    Intern Med; 2012; 51(18):2573-9. PubMed ID: 22989829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further evidence for a marfanoid syndrome with neonatal progeroid features and severe generalized lipodystrophy due to frameshift mutations near the 3' end of the FBN1 gene.
    Goldblatt J; Hyatt J; Edwards C; Walpole I
    Am J Med Genet A; 2011 Apr; 155A(4):717-20. PubMed ID: 21594992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy.
    Jéru I; Vantyghem MC; Bismuth E; Cervera P; Barraud S; ; Auclair M; Vatier C; Lascols O; Savage DB; Vigouroux C
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6025-6032. PubMed ID: 31504636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.
    Agarwal AK; Garg A
    J Clin Endocrinol Metab; 2002 Jan; 87(1):408-11. PubMed ID: 11788685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia.
    Karhan AN; Zammouri J; Auclair M; Capel E; Apaydin FD; Ates F; Verpont MC; Magré J; Fève B; Lascols O; Usta Y; Jéru I; Vigouroux C
    Eur J Endocrinol; 2021 Nov; 185(6):841-854. PubMed ID: 34643546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy.
    Kim CA; Delépine M; Boutet E; El Mourabit H; Le Lay S; Meier M; Nemani M; Bridel E; Leite CC; Bertola DR; Semple RK; O'Rahilly S; Dugail I; Capeau J; Lathrop M; Magré J
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1129-34. PubMed ID: 18211975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a caveolin-1 mutation associated with both pulmonary arterial hypertension and congenital generalized lipodystrophy.
    Han B; Copeland CA; Kawano Y; Rosenzweig EB; Austin ED; Shahmirzadi L; Tang S; Raghunathan K; Chung WK; Kenworthy AK
    Traffic; 2016 Dec; 17(12):1297-1312. PubMed ID: 27717241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy.
    Zolotov S; Xing C; Mahamid R; Shalata A; Sheikh-Ahmad M; Garg A
    Am J Med Genet A; 2017 Jan; 173(1):190-194. PubMed ID: 27862896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A disease-associated frameshift mutation in caveolin-1 disrupts caveolae formation and function through introduction of a de novo ER retention signal.
    Copeland CA; Han B; Tiwari A; Austin ED; Loyd JE; West JD; Kenworthy AK
    Mol Biol Cell; 2017 Nov; 28(22):3095-3111. PubMed ID: 28904206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
    Francis GA; Li G; Casey R; Wang J; Cao H; Leff T; Hegele RA
    BMC Med Genet; 2006 Jan; 7():3. PubMed ID: 16412238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juvenile-onset generalized lipodystrophy due to a novel heterozygous missense LMNA mutation affecting lamin C.
    Patni N; Xing C; Agarwal AK; Garg A
    Am J Med Genet A; 2017 Sep; 173(9):2517-2521. PubMed ID: 28686329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2.
    Morel CF; Thomas MA; Cao H; O'Neil CH; Pickering JG; Foulkes WD; Hegele RA
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2689-95. PubMed ID: 16636128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
    Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E
    Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.